ECM
MRNA icon

Endurant Capital Management’s Moderna MRNA Stock Holding History

Endurant Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-36,130
Closed -$5.55M – 50
2023
Q1 		$5.55M Buy
+36,130
New +$5.96M 2.85% 11

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Endurant Capital Management's MRNA Position: Q2 2023 in Review

Endurant Capital Management sold out of Moderna (MRNA) in Q2 2023, closing a stake of 36,130 shares — an estimated $5.55M sold.

Endurant Capital Management first reported a position in MRNA in Q1 2023 and held it in 1 quarter. The position peaked at $5.55M in Q1 2023. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Endurant Capital Management reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Endurant Capital Management sold 36,130 Moderna shares in Q2 2023, an estimated $5.55M.
  • Endurant Capital Management first reported a position in Moderna in Q1 2023 and held it in 1 quarter.
  • Endurant Capital Management's Moderna position peaked at $5.55M in Q1 2023.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.